Abstract | BACKGROUND: Initiation of antiretroviral therapy (ART) often leads to weight gain. While some of this weight gain may be an appropriate return-to-health effect, excessive increases in weight may lead to obesity. We sought to explore factors associated with weight gain in several randomized comparative clinical trials of ART initiation. METHODS: We performed a pooled analysis of weight gain in 8 randomized controlled clinical trials of treatment-naive people living with human immunodeficiency virus (HIV) initiating ART between 2003 and 2015, comprising >5000 participants and 10 000 person-years of follow-up. We used multivariate modeling to explore relationships between demographic factors, HIV disease characteristics, and ART components and weight change following ART initiation. RESULTS: CONCLUSIONS:
Weight gain is ubiquitous in clinical trials of ART initiation and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens as contributors. The mechanisms by which certain ART agents differentially contribute to weight gain are unknown.
|
Authors | Paul E Sax, Kristine M Erlandson, Jordan E Lake, Grace A Mccomsey, Chloe Orkin, Stefan Esser, Todd T Brown, Jürgen K Rockstroh, Xuelian Wei, Christoph C Carter, Lijie Zhong, Diana M Brainard, Kathleen Melbourne, Moupali Das, Hans-Jürgen Stellbrink, Frank A Post, Laura Waters, John R Koethe |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 71
Issue 6
Pg. 1379-1389
(09 12 2020)
ISSN: 1537-6591 [Electronic] United States |
PMID | 31606734
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. |
Chemical References |
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
|
Topics |
- Anti-HIV Agents
(adverse effects)
- Anti-Retroviral Agents
(adverse effects)
- Female
- HIV Infections
(drug therapy)
- Humans
- Risk Factors
- Tenofovir
(therapeutic use)
- Weight Gain
|